The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Ninlaro Filed in Japan for Post-Transplant Maintenance: Takeda
Takeda Pharmaceutical said on April 25 that it has filed an application seeking a new indication for its multiple myeloma (MM) drug Ninlaro (ixazomib) as a post-autologous stem cell transplant (ASCT) maintenance therapy. Ninlaro hit the Japan market in May…
To read the full story
Related Article
- Takeda Drops US Filing for Ninlaro Label Expansion, Plans Resubmission with OS Data
February 4, 2019
- Ninlaro Shows 39% Improvement in PFS in Post-Transplant Multiple Myeloma Patients: Takeda
December 4, 2018
- Ninlaro Hits Primary Endpoint in Post-Transplant Multiple Myeloma: Takeda
July 13, 2018
- Ninlaro Makes Japan Debut, Mundesine Now Also Available
May 25, 2017
BUSINESS
- Teikoku to Market Medipost’s Knee OA Cell Therapy in Japan
December 22, 2025
- Clinigen Japan Adds 4 Products, Including Takeda’s Buccolam
December 22, 2025
- Meiji Backs US Incubator MBC BioLabs to Boost Open Innovation
December 22, 2025
- Boehringer Passes on Option for Nxera’s Schizophrenia Program
December 22, 2025
- Otsuka Kicks Off Global PIII of Phenylketonuria Drug
December 22, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…